Phase 4 Study of Laybon Tab. in Knee Osteoarthritis

This Phase 4, multicenter, randomized, double-blind, active-controlled, parallel study aims to evaluate the non-inferiority of Laybon Tab. compared to Layla Tab. (PMG Pharm Co., Ltd.) in patients with knee osteoarthritis. Participants will receive either Laybon Tab. or Layla Tab. for 8 weeks. The primary outcome is the change in knee pain during activity, assessed by a 100 mm pain VAS over the previous 24 hours.

NCT Number	NCT07203547
Lead Sponsor	Mather's Pharm. Co., Ltd.
Conditions	Osteoarthritis, Knee, Osteoarthritis
Enrollment	172 participants
Start Date	2025-12
Primary Completion	2027-12 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2025-10-02